Brickell Biotech Inc

Brickell Biotech — Vical — Merger or Acquisition (June 2019)

18 slides from Brickell Biotech's merger presentation, Jun 3, 2019

  1. Slide 1: Brickell Biotech and Vical Merger: Making Fresh Tracks in Dermatology

    Brickell Biotech, Inc. and Vical Incorporated Merger Making Fresh Tracks in DermatologyⓇ June 2019 Exhibit 99.3

  2. Slide 2: Safe Harbor

    Safe Harbor Any statements made in this presentation relating to future financial, business and/or research and clinical performance, conditions, plans, prospects, trends, or strategies and other such matters, including without limitation, the potential closing of the proposed merger between Vical a

  3. Slide 3: Additional Information about the Merger and Where to Find It

    Additional Information about the Merger and Where to Find It Non-Solicitation This communication does not constitute an offer to sell or solicitation of an offer to buy any securities or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any jurisdiction

  4. Slide 4: Merger Aimed at Creating a Leading Innovative Dermatology Company

    Merger Aimed at Creating a Leading Innovative Dermatology Company Brickell and Vical (NASDAQ:VICL) announced signing of a definitive merger agreement on June 3 Follows Vical’s comprehensive review of strategic alternatives All-stock transaction expected to be completed in third quarter of 2019 Trans

  5. Slide 5: Brickell Highlights: Striving to be Best-in-Class in Dermatology

    Brickell Highlights: Striving to be Best-in-Class in Dermatology Pipeline focused on three differentiated NCEs targeting skin diseases with significant unmet medical needs Goal to develop potential best-in-class product candidates Multiple issued patents with terms extending into the 2030s Sofpironi

  6. Slide 6: Executing Strategy with Experienced Leadership Team

    Brickell executives have successfully developed and launched numerous products achieving first-in-class and/or blockbuster status Executing Strategy with Experienced Leadership Team Deepak Chadha Chief R&D Officer Robert Brown Chief Executive Officer Andy Sklawer Co-Founder & COO Gary Walker Chief M

  7. Slide 7: Pipeline of NCEs with Significant Potential in Dermatology

    Pipeline of NCEs with Significant Potential in Dermatology PRODUCT CANDIDATE MOA & INDICATION PRE-CLINICAL PHASE 1 PHASE 2A PHASE 2B PHASE 3 ANTICIPATED KEY MILESTONES Sofpironium Bromide Topical soft anticholinergic for axillary hyperhidrosis Positive Pivotal P3 results received in March 2019 (Japa

  8. Slide 8: Significant U.S. Market Opportunity in Hyperhidrosis

    Significant U.S. Market Opportunity in Hyperhidrosis 1Hyperhidrosis: An update on prevalence and severity of hyperhidrosis in the United States, Doolittle, James, October 2016 2Prevalence of primary focal hyperhidrosis among teens 12-17 in US Population, Glaser, Ballard, Pieretti, Pariser, March 201

  9. Slide 9: Sofpironium Bromide: Potential Best-in-Class Therapy for Hyperhidrosis

    Sofpironium Bromide: Potential Best-in-Class Therapy for Hyperhidrosis SEQUENCE OF THERAPEUTIC OPTIONS Current Therapies Sofpironium Bromide* Antiperspirants Botox & devices (2nd line) Surgery 2nd ★ Clinical Strength OTC X Anticholinergics (new 1st line) *Not approved and safety and efficacy has not

  10. Slide 10: Sofpironium Bromide: A Novel Soft Anticholinergic

    Sofpironium Bromide: A Novel Soft Anticholinergic Retro-metabolically designed Provides the potential for enhanced therapeutic effect with minimal systemic side effects Allows for various dosage strengths Short plasma half life Rapid metabolic deactivation and fast elimination Potential for a more f

  11. Slide 11: Target Product Profile: Sofpironium Bromide

    Target Product Profile: Sofpironium Bromide MOLECULE Sofpironium bromide MOA Soft-anticholinergic (rapidly metabolized into inactive metabolite) FORMULATION / ADMINISTRATION Gel in a metered dose pump directly applied to underarms via applicator cap SAFETY MOA creates potential for fewer systemic AE

  12. Slide 12: Sofpironium Bromide Clinical & Regulatory Overview

    Sofpironium Bromide Clinical & Regulatory Overview Brickell expects to complete all activities required to submit a NDA Q2 2021 FDA aligned with overall development plan Phase 3 study design and co-primary efficacy endpoints Achieved Statistical Significance in Phase 2b Studies Demonstrated safety,

  13. Slide 13: U.S. Phase 2b Study: Summary of Results

    3 U.S. Phase 2b Study: Summary of Results Sofpironium bromide (SB) gel, 15% demonstrated statistically significant response for absolute GSP reduction and all doses demonstrated statistically significant responses for HDSM-Ax; Most common AEs were dry mouth and blurred vision which were predominantl

  14. Slide 14: Value of the Kaken Partnership to Brickell

    Net Sales of $1B (2018); R&D spend over $100M Developed & Launched Jublia/Clenafin (anti-fungal) Sofpironium Bromide is most advanced clinical stage asset Value of the Kaken Partnership to Brickell Positive Phase 3 Topline Results Significant Upfront & Potential Near-Term Sales Milestones & Royaltie

  15. Slide 15: Pivotal Phase 3 Study Overview (2 Identical Studies)

    Pivotal Phase 3 Study Overview (2 Identical Studies) Phase 3 study design is based on Phase 2b; Planning is well underway and on track for initiation in Q4 2019 with topline results expected in Q4 2020 A multicenter, randomized, double-blinded, vehicle-controlled study to evaluate the safety and eff

  16. Slide 16: Key Achieved & Anticipated Development Milestones

    Sofpironium Bromide – Axillary Hyperhidrosis Completion of Enrollment of Phase 3 Long-term Safety in US ü Completion of P3 pivotal studies & positive topline results in Japan ü Initiation of Phase 3 pivotal studies in US Q4 2019 Completion of Phase 3 pivotal studies in US Q4 2020 NDA Submission Q2 2

  17. Slide 17: Merger Enables Value-Creation Opportunities

    Merger Enables Value-Creation Opportunities Starting Phase 3 in U.S. with a potential best-in-class, late-stage asset for hyperhidrosis An underserved and large market, just starting to gain attention, with significant growth potential Positive Phase 2b data in the U.S., successful Phase 3 in Japan,

  18. Slide 18: Brickell Biotech and Vical Merger: Contact

    Brickell Biotech, Inc. and Vical Incorporated Merger Making Fresh Tracks in DermatologyⓇ June 2019 Contact: [email protected]

Vical — Merger or Acquisition (June 2019) on 6ix